Invests in categories: BioTechCareDevelopmentHardwareHealthTechMedTechPlatformProductServiceTechnology
SV Health Investors is a specialist healthcare fund manager, investing across multiple stages and sectors. Our goal is to transform healthcare one investment at a time.
News
659
Portfolio
65
Persons
58
Mentions
103
Employees: 51-200
Investment Stage: Series B
Portfolio 65
Show more
Persons 58
| Date | First Name | Last Name | Title | Location | |||
| - | Alex | Badamchi-Z... | Vice Presi... | - | - | - | |
| - | Kerry | Spellman | Executive ... | - | - | - | |
| - | Luke | Johnson | Operating ... | - | - | - | |
| - | A.J. | Rossi | Partner | - | - | - | |
| - | Brett | Haumann | Venture Pa... | - | - | - | |
| - | Ceri | Davies | Member | - | - | - | |
| - | Charles | Dunn | Principal | - | - | - | |
| - | Andrew | Cappetta | Vice Presi... | - | - | - | |
| - | Nicole | Cox | Executive ... | - | - | - | |
| - | Georgia | Frost | Vice Presi... | - | - | - | |
| - | Luke | Devey | Venture Pa... | - | - | - | |
| - | Laurence | Barker | Partner | - | - | - | |
| - | Jean | Rivera Iri... | Associate | - | - | - | |
| - | Celina | Lee | Gradiant i... | - | - | - | |
| - | Eugene | Hill | Chairman | - | - | - | |
| - | Emily | Gaudiano | Senior Ass... | - | - | - | |
| - | Vineela | Kanagala | Senior Ass... | - | - | - | |
| - | Stacey | Jolin | Executive ... | - | - | - | |
| - | Roopam | Chandaria | Financial ... | - | - | - | |
| - | Susan | Kohlhaas | Member | - | - | - | |
| - | Christian | Jung | Partner | - | - | - | |
| - | Maria | Carrillo | Member | - | - | - | |
| - | Tim | Harris | Operating ... | - | - | - | |
| - | Karyn | Ragonese | Executive ... | - | - | - | |
| - | Miles | Gerson | Partner | - | - | - | |
| - | Ashley | Pulcini | Executive ... | - | - | - | |
| - | James | Costine | Chief Fina... | - | - | - | |
| - | Fiona | Elwood | Member | - | - | - | |
| - | Paul | LaViolette | Managing P... | - | - | - | |
| - | Niranjan | Bose | Member | - | - | - | |
| - | Jonathan | Mott | Chief Comp... | - | - | - | |
| - | Anne | Phelan | Member | - | - | - | |
| - | Rana | Al-Hallaq | Member | - | - | - | |
| - | Georgina | Ewels | Director, ... | - | - | - | |
| - | Kelly | Bales | Member | - | - | - | |
| - | Lisa | Broad | Member | - | - | - | |
| - | Joanna | Wolak | Venture Pa... | - | - | - | |
| - | Inna | Walker | Business S... | - | - | - | |
| - | Freya | Easton | Senior Ass... | - | - | - | |
| - | Michael | Hutton | Venture Pa... | - | - | - | |
| - | Nikki | Hecht | Executive ... | - | - | - | |
| - | Dan | Burgess | Operating ... | - | - | - | |
| - | Lennart | Spindler | Associate | - | - | - | |
| - | John | Lyons | Member | - | - | - | |
| - | Ross | Jeggo | Member | - | - | - | |
| - | Kate | Bingham | Managing P... | - | - | - | |
| - | Dylan | Arpey | Director, ... | - | - | - | |
| - | Hannah | Maunder | Senior Ass... | - | - | - | |
| - | Michael | Ugwueke DH... | President ... | - | - | - | |
| - | Richard | Hargreaves | Member | - | - | - | |
| - | Jonathan | Behr | Partner | - | - | - | |
| - | Bryce | Hewitt | Finance As... | - | - | - | |
| - | Ali | Jazayeri | Operating ... | - | - | - | |
| - | Anne | Marie Garr... | Executive ... | - | - | - | |
| - | Neil | Weir | Venture Pa... | - | - | - | |
| - | Ruth | McKernan | Operating ... | - | - | - | |
| - | Charles | Large | Venture Pa... | - | - | - | |
| - | Tom | Patton | Operating ... | - | - | - |
Show more
News 659
| Date | Title | Description |
| 09.09.2026 | SV is hiring: Associate / Sr Associate – Dementia Discovery Fund | Position Title: Associate / Sr Associate – Dementia Discovery Fund, SV Health Investors Location: Boston Office Start Date: Immediate Compensation: Competitive About the Opportunity The Dementia Discovery Fund (DDF) is seeking an ambitious ... |
| 08.09.2026 | Prilenia Appoints Frederick (Rick) Munschauer, MD, FAAN, as Chief Medical Officer | NAARDEN, Netherlands & WALTHAM, Mass.--(BUSINESS WIRE)-- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s d... |
| 28.08.2026 | TRexBio Announces Positive Topline Results from First-in-Human Phase 1a Study of TRB-061, a TNFR2 Agonist in Clinical Development for Atopic Dermatitis | SOUTH SAN FRANCISCO, Calif., August 26, 2026 – TRex Bio, Inc. (“TRexBio”), a clinical-stage biotechnology company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines, today announced unblinded topl... |
| 17.08.2026 | Leal Therapeutics Announces $30 Million Series A Extension and Initiation of Phase 1b/2a Clinical Trial of LTX-001 in Schizophrenia | WORCESTER, Mass., Aug. 17, 2026 /PRNewswire/ -- Leal Therapeutics, Inc. (Leal), a clinical-stage biopharmaceutical company developing first-in-class neuro-metabolic therapeutics, today announced a second close of $30 million of its Series A... |
| 10.08.2026 | AstronauTx exercises option from Saniona to acquire worldwide rights to neurological disease program under research collaboration | Saniona (OMX: SANION), a clinical-stage biopharmaceutical company focused on neurological and psychiatric disorders, and AstronauTx Ltd ("AstronauTx"), a biotechnology company developing therapeutics to treat neurological disorder... |
| 03.08.2026 | NRG Therapeutics Announces the Appointment of Claus Sundgreen M.D. as Chief Medical Officer | Stevenage, UK, 3 August 2026 - NRG Therapeutics Ltd. (“NRG”), a clinical stage neuroscience company developing novel disease-modifying therapeutics that rectify mitochondrial dysfunction in neurodegenerative diseases, is pleased to announce... |
| 15.07.2026 | AdvanCell Closes US $315 Million Oversubscribed Series D Financing to Advance Targeted Alpha Therapies and Expand Clinical and Commercial Manufacturing Infrastructure | • Oversubscribed financing led by Ally Bridge Group and co-led by Alpha Wave, with participation from new investors Bain Capital Life Sciences, Fidelity Management & Research Company, T. Rowe Price, a leading sovereign wealth fund, Even... |
| 14.07.2026 | Draig Therapeutics Closes Oversubscribed $65 Million Series B to Accelerate Development of Highly Specific AMPA and GABAA Receptor Modulators in Neuropsychiatric Disorders | Financing led by new investor, Deep Track Capital with participation from Janus Henderson Investors and Marshall Wace among other investors Proceeds will support accelerated clinical advancement of company’s pipeline, including lead program... |
| 09.07.2026 | Alchemab Therapeutics announce biggest ever life sciences investment from British Business Bank to advance its AI-enabled clinical pipeline of next generation human-derived antibodies | CAMBRIDGE, UK – Clinical-stage biotech Alchemab Therapeutics has extended its series A financing with a £25 million (USD $34m) investment from the British Business Bank – the Bank’s largest investment in a life sciences company to date. The... |
| 07.07.2026 | Prilenia and Ferrer Announce Initiation of the Confirmatory PRECISE-HD Study of Pridopidine in Huntington’s Disease | PRECISE-HD (Pridopidine Phase 3 Study to Establish Clinical Impact and Safety in Huntington’s Disease (HD)) is designed to further evaluate the efficacy and safety of pridopidine, an oral investigational drug, on disease progression, functi... |
| 23.06.2026 | TRIMTECH Therapeutics brings total seed round to $47M with additional investment of $14M to further develop TRIMTAC and TRIMGLUE targeted protein degradation portfolio | Cambridge, UK, 23 June 2026: TRIMTECH Therapeutics (TRIMTECH or the Company), a biotechnology company developing novel small molecule therapies that target and degrade protein aggregates associated with neurodegenerative diseases, today ann... |
| 16.06.2026 | AviadoBio Expands vMiX™ Precision Gene Silencing Platform Exclusive License Agreement with King’s College London Beyond Neurological Diseases to All Human Therapeutic Areas | • vMiX™ is a vectorized RNA interference (RNAi) platform combining knockdown, cell-specific expression with the flexibility to target multiple genes • Update follows recent positive AVB-406 preclinical data presented at ASGCT, supporting th... |
| 09.06.2026 | Harness Therapeutics Awarded Grant from The Michael J. Fox Foundation for Parkinson’s Research to Advance Parkinson's Disease Programme | Cambridge, UK, 9 June 2026: Harness Therapeutics (‘Harness’), a biotechnology company unlocking previously undruggable targets to transform the treatment of neurodegenerative diseases, today announces it has been awarded a grant from The Mi... |
| 09.06.2026 | Montara Therapeutics Appoints Andrew Miller to Board of Directors, Names Chief Medical Officer, and Promotes Chief Technology Officer | SAN FRANCISCO, June 9, 2026 – Montara Therapeutics, a biotechnology company pioneering brain-selective therapies for CNS diseases, today announced the appointment of Andrew Miller, Ph.D., to its Board of Directors; the hiring of David Miche... |
| 08.06.2026 | Amphista Therapeutics announces FDA clearance of IND application for AMX-883, its lead Targeted Glue™ degrader for acute myeloid leukaemia | Cambridge, UK, 8 June 2026 – Amphista Therapeutics (“the Company” or “Amphista”), a leader in the discovery and development of next generation targeted protein degradation (TPD) medicines, today announces that the U.S. Food and Drug Adminis... |
| 02.06.2026 | Montara Therapeutics Receives Research Grant from The Michael J. Fox Foundation to Advance Parkinson’s Disease Program | Building on a prior MJFF-funded collaboration targeting LRRK2, Montara’s BrainOnly™ platform now targets the mTOR pathway — exploring a class of drugs with longstanding scientific interest but a history of safety challenges. SAN FRANCISCO, ... |
| 26.05.2026 | Prilenia Donates Clinical Trial Datasets to CHDI Foundation to Advance Huntington's Disease Research | NAARDEN, The Netherlands & WALTHAM, Mass.--(BUSINESS WIRE)-- Prilenia Therapeutics B.V. today announced a Data Use Agreement (DUA) under which Prilenia will provide CHDI with clinical data from the placebo arms of its PRIDE and PROOF st... |
| 26.05.2026 | Artios Announces First Patient Dosed in Randomized Phase 2 POLKA Study Evaluating DNA Polymerase Theta Inhibitor ART6043 in gBRCA-mutated HER2-Negative Breast Cancer | Key milestone positions ART6043 as the most advanced Pol-theta inhibitor in clinical development; the potentially first-in-class program is supported by U.S. FDA Fast Track designation CAMBRIDGE, United Kingdom and NEW YORK, May 26, 2026 – ... |
| 19.05.2026 | Mestag Therapeutics Announces the First Patient Dosed with MST-0312 in the Phase I STARLYS Trial | — STARLYS trial to evaluate the potential of MST-0312, a targeted lymphotoxin-beta (LTBR) agonist bispecific antibody, as a novel therapeutic strategy for the treatment of solid tumors. — Study to evaluate tertiary lymphoid structure (TLS) ... |
| 14.05.2026 | AviadoBio Presents Positive Preclinical Data for AVB-406 Program in Alzheimer’s Disease and Other Tauopathies at ASGCT 2026 | LONDON – May 14, 2026 – AviadoBio, a pioneering gene therapy company dedicated to developing and delivering potentially transformative medicines for neurodegenerative disorders, today announced positive preclinical data for the AVB-406 prog... |
| 13.05.2026 | Boehringer Ingelheim licenses novel oral therapeutics program for immune diseases from Sitryx Therapeutics | Ingelheim, Germany, Oxford, UK and Boston, USA, 26, February 2026 – Boehringer Ingelheim and Sitryx Therapeutics (“Sitryx”), a clinical-stage biopharmaceutical company developing novel oral therapies to restore immune balance in autoimmune ... |
| 13.05.2026 | Violet Therapeutics Raises $4.75M Seed Extension to Advance Novel Therapeutic for Synaptic Preservation and Repair | CAMBRIDGE, MA, UNITED STATES, May 13, 2026 / Violet Therapeutics (“Violet”), a biotechnology company developing first-in-class therapies for neurodegenerative diseases, today announced the closing of a $4.75M seed extension financing. The f... |
| 13.05.2026 | Rondo Therapeutics Doses First Patient in Phase 1 Trial of RNDO-564, a First-in-Class Co-Stimulatory Bispecific Antibody Targeting Nectin-4 in Advanced Solid Tumors | Novel CD28 x Nectin-4 bispecific designed to overcome limitations of ADCs through durable and well-tolerated tumor-directed immune co-stimulation Milestone marks Rondo Therapeutics’ transition to a clinical-stage company HAYWARD, Calif.--(... |
| 12.05.2026 | Cerevance Completes Enrollment in Pivotal Phase 3 Parkinson’s Disease Trial and Closes Oversubscribed $20 Million Series C to Extend Runway into 2027 | Boston – MAY 12, 2026 – Cerevance, a clinical-stage biopharmaceutical company advancing targeted therapies for neurodegenerative diseases and obesity, today announced completion of patient enrollment in the pivotal Phase 3 ARISE trial evalu... |
| 12.05.2026 | AstronauTx builds executive team with appointment of experienced clinical development leader Michelle Mellion, MD as Chief Medical Officer | London, UK, 12 May 2026 – AstronauTx Ltd (“AstronauTx”), a biotechnology company developing therapeutics to treat Alzheimer’s Disease and other neurological disorders by improving sleep architecture, announces the appointments of Dr. Michel... |
| 28.04.2026 | Prilenia Appoints Dr. Elisabeth Leiderman as Chief Financial Officer | NAARDEN, The Netherlands & WALTHAM, Mass.--(BUSINESS WIRE)-- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington... |
| 27.04.2026 | AviadoBio Announces Agreement with Apertura Gene Therapy to License TfR1 CapX™, a Next-Generation Blood-Brain Barrier-Crossing Capsid | LONDON and NEW YORK – April 27, 2026 – AviadoBio Ltd.(“AviadoBio”) and Apertura Gene Therapy (“Apertura”), a biotechnology company developing next-generation AAV capsids for delivering genetic medicines, today announced a licensing agreemen... |
| 13.04.2026 | Leal Therapeutics Announces Executive Leadership Appointments and Provides Business Update | WORCESTER, MA – April 13, 2026 – Leal Therapeutics, Inc. (Leal), a biotechnology company developing neuro-metabolic therapeutics, today announced the appointments of Johannes Tauscher, M.D., as Chief Medical Officer and Raymond Jordt, M.B.A... |
| 02.04.2026 | SV Health Investors Acquires EpiVax | BOSTON--(BUSINESS WIRE)--SV Health Investors (“SVHI”), a healthcare and life sciences focused private investment firm, announced today the acquisition of EpiVax, Inc. Headquartered in Providence, RI, EpiVax is a leading bioanalytical CRO sp... |
| 31.03.2026 | AviadoBio Advances AVB-101 Gene Therapy Program and Initiates Fourth Dose-Escalation Cohort of Phase 1/2 ASPIRE-FTD Trial | Early biomarker and safety data show encouraging signals with plans to present additional data in 2H 2026 AviadoBio secures strategic investment from The Alzheimer’s Drug Discovery Foundation (ADDF) and The Association for Frontotemporal De... |
| 30.03.2026 | Prilenia and Ferrer Announce First Participant Enrolled in the “PREVAiLS” Phase 3 Study of Pridopidine in ALS | REVAiLS is a pivotal, global, 500-participant Phase 3 study to evaluate efficacy and safety of pridopidine, an investigational drug, in slowing ALS progression (ALSFRS-R) in early, rapidly progressive participants The design of the potentia... |
| 17.03.2026 | Mestag Therapeutics Announces $40 Million Financing and Appoints Chief Medical Officer and Chief Development Officer in Preparation to Enter the Clinic | -- Financing brings total funds committed to date to >$95 million -- Proceeds support the STARLYS clinical trial evaluating targeted LTBR agonist MST-0312 in solid tumors, together with platform and pipeline activities in inflammatory di... |
| 17.03.2026 | Perfuze Receives FDA Clearance for Millipede88® — the First Super-Bore Aspiration Catheter Cleared for Standalone Direct Aspiration | GALWAY, Ireland --Perfuze, a medical device company dedicated to advancing stroke treatment through next-generation catheter technology, today announced it has received FDA 510(k) clearance for the Millipede88® Aspiration Catheter. The clea... |
| 03.03.2026 | Quell Therapeutics Initiates CHILL Phase 1/2 Trial of Novel QEL-005 CAR Treg Therapy in Refractory Rheumatoid Arthritis and Systemic Sclerosis Following UK CTA Approval | London, UK – 3 March, 2026 – Quell Therapeutics Ltd (“Quell”), today announced that it has initiated a Phase 1/2 basket clinical study evaluating its autologous CAR-Treg therapy, QEL-005, in patients with Rheumatoid Arthritis and Systemic S... |
| 03.03.2026 | Quell Therapeutics Demonstrates Safety, Phenotypic Stability, Durability and Early Efficacy with Phenotype‑Locked™ CAR‑Tregs in LIBERATE Phase 1/2 Liver Transplant Study | London, UK – 3 March, 2026 – Quell Therapeutics Ltd (“Quell”), a leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, today shared interim top-line data from its LIBE... |
| 24.02.2026 | QurAlis Demonstrates Effects on Disease Progression and Target Engagement in ANQUR Clinical Trial of QRL-201, a First-in-Class Precision Medicine in Development for Sporadic ALS | CAMBRIDGE, Mass., February 24, 2026 – QurAlis Corporation (“QurAlis”), a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that have the potential to alter the trajectory of neurodegener... |
| 17.02.2026 | Pivot Point Consulting Emerges as a Unified Healthcare IT Powerhouse Following Its Acquisition by Innovative Consulting Group | PANAMA CITY, Fla., Feb. 17, 2026 /PRNewswire/ -- SV Health Investors, Health Enterprise Partners and Petra Capital Partners today announced that Innovative Consulting Group, a portfolio company of SV Health Investors, has acquired Pivot Poi... |
| 16.02.2026 | Harness Therapeutics Nominates HRN001, a First-in-Class Drug Candidate for Huntington’s Disease and Establishes Clinical Advisory Board | Cambridge, UK, 16 February 2026: Harness Therapeutics (‘Harness’), a biotechnology company unlocking previously undruggable targets to transform the treatment of neurodegenerative diseases, today announces the nomination of HRN001 as its le... |
| 02.02.2026 | AdvanCell Announces Collaboration and Exclusive Licensing Agreement with 48Hour Discovery to Develop a Novel Peptide-Based Lead-212 Radiotherapeutic for a Gastrointestinal Cancer with Significant Medi... | Brisbane, Australia and Boston, USA – February 2, 2026 – AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, today announced that it has entered into a Collaboration and Exclusi... |
| 27.01.2026 | TRexBio Closes $50 Million Financing to Support a Growing Clinical-Stage Immunology Pipeline of Tissue-Targeted Treg Therapeutics | SOUTH SAN FRANCISCO, January 27, 2026 – TRex Bio, Inc. (“TRexBio”), a clinical-stage biotechnology company discovering and developing precision immunoregulatory medicines based on tissue Treg biology, today announced the close of an oversub... |
| 26.01.2026 | Sitryx advances development of PKM2 modulator SYX-5219 into atopic dermatitis patients following clinical evidence of immunomodulatory activity | Oxford, UK and Boston, MA – January 26, 2026 – Sitryx Therapeutics (“Sitryx” or “the Company”), a clinical-stage biopharmaceutical company developing novel oral therapies to restore immune balance in autoimmune and inflammatory disease, has... |
| 20.01.2026 | SV Health Investors Appoints Miles Gerson as Partner | Former Head of Takeda Ventures to Co‑Lead the Dementia Discovery Funds and Expand U.S. Investment Activities London and Boston, 9 January 2026 – SV Health Investors ("SV") today announced the appointment of Miles Gerson as Partner... |
| 16.01.2026 | Three SV-created biotech companies included in The Times’ ‘100 Tech Ones to Watch’ | The Times article 'The great minds turning science into multimillion dollar companies' highlights the three SV-created biotech companies included in The Times’ ‘100 Tech Ones to Watch’ this year. All three were co-founded by SV Operating Pa... |
| 14.01.2026 | FDA Approves Updated Label for Miach Orthopaedics’ BEAR® Implant to Include Significantly Lower Risk of Osteoarthritis | WESTBOROUGH, Massachusetts – January 14, 2026 – Miach Orthopaedics, Inc., a company transforming the treatment of anterior cruciate ligament (ACL) tears, today announced that the U.S. Food and Drug Administration has granted 510(k) clearanc... |
| 13.01.2026 | HPS/PayMedix Secures $33 Million Investment | MILWAUKEE, Jan. 13, 2026 /PRNewswire/ -- HPS/PayMedix, the leading healthcare financing and payments solutions provider, today announced it has closed $33 million in equity and debt financing to accelerate the growth of its groundbreaking P... |
| 08.01.2026 | NRG Therapeutics Announces First Participants Dosed in its First-in-Human Phase 1 Clinical Trial of NRG5051 Which is Being Developed as a Disease-modifying Treatment for ALS/MND and Parkinson’s | Stevenage, UK, 8 January 2026 - NRG Therapeutics Ltd. (“NRG”), a clinical stage neuroscience company targeting a novel mechanism to rectify mitochondrial dysfunction in neurodegenerative diseases, is pleased to announce that the first parti... |
| 07.01.2026 | CSA Medical Submits PMA for RejuvenAir® System Following Positive Results from Pivotal SPRAY-CB Trial | BOSTON, Jan. 7, 2026 /PRNewswire/ -- CSA Medical, Inc., a medical device company focused on interventional pulmonary therapies, today announced the submission of a Premarket Approval (PMA) application to the U.S. Food and Drug Administratio... |
| 07.01.2026 | AstronauTx appoints experienced biotech executive Adam Rosenberg as Chair of the Board | London, UK, 7 January 2026 – Astronautx Ltd (“AstronauTx”), a biotechnology company developing therapeutics to treat Alzheimer’s Disease and other neurological disorders by improving sleep architecture, today announces the appointment of Ad... |
| 06.01.2026 | LoQus23 Therapeutics nominates LQT-23 as first-in-class, oral drug candidate for Huntington’s Disease | Cambridge, UK, 6 January 2026 – LoQus23 Therapeutics Ltd (“LoQus23”), a biotechnology company investigating small molecule drugs that could stop the pathogenic triplet expansion that is the cause and driver of Huntington’s Disease (HD), myo... |
| 11.12.2025 | Prilenia and Ferrer Announce FDA Clearance to Start the “PREVAiLS” Pivotal Phase 3 Study with Pridopidine in ALS | FDA clearance received to start the pivotal, 500-patient, placebo-controlled Phase 3 “PREVAiLS” study of pridopidine in participants with early, rapidly progressive ALS; US recruitment set to begin early 2026 PREVAiLS (Pridopidine Phase 3 S... |
| 08.12.2025 | Amphista Therapeutics presents new preclinical data showing the potential of its BRD9 Targeted Glue™, AMX-883, to transform the treatment paradigm for acute myeloid leukaemia | Cambridge, UK, 8 December 2025 – Amphista Therapeutics (“the Company” or “Amphista”), a leader in the discovery of next generation targeted protein degradation (TPD) medicines, today announces that full details of its new preclinical data w... |
| 02.12.2025 | TRIMTECH Therapeutics appoints Alison Lawton as Chair of the Board | Cambridge, UK, 2 December 2025: TRIMTECH Therapeutics, a biotechnology company developing novel small molecule therapies that target and degrade protein aggregates associated with neurodegenerative diseases, today announced the appointment ... |
| 25.11.2025 | Amphista Therapeutics announces AMX-883 data to be presented at the ASH Annual Meeting and Exposition and provides a business progress update | Cambridge, UK, 25 November 2025 – Amphista Therapeutics (“the Company” or “Amphista”), a leader in the discovery of next generation targeted protein degradation (TPD) medicines, today announces the presentation of new preclinical data with ... |
| 17.11.2025 | Imbria Pharmaceuticals Announces Extension of Series B Financing to Advance Ninerafaxstat for Cardiovascular Diseases | New investor AXA IM Alts joins upsized Series B round to support clinical advancement and expand global health impact of ninerafaxstat, a novel cardiovascular therapeutic Dr. Zina Affas Besse (AXA IM Alts) and Mr. Ken Horne (AN Ventures) ap... |
| 17.11.2025 | AdvanCell Appoints Philina Lee, PhD as Chief Executive Officer to Lead US Expansion and Drive Global Growth | Dr Lee is a seasoned biopharmaceutical executive with a proven track record of leading cross-functional teams to successfully develop and commercialize innovative therapies in oncology Sydney, Australia and Boston, MA, USA – November 17, 20... |
| 17.11.2025 | Artios, an SV-created company, has announced its over-subscribed $115m Series D financing, which will fund the expansion of the clinical evaluation of Artios’ lead programme, alnodesertib | Artios Announces Oversubscribed $115 Million Series D Financing to Accelerate Clinical Programs in Indications of High Unmet Need Funding advances Phase 2 expansion cohorts in pancreatic and colorectal cancer in ATM-negative patients for Ar... |
| 03.11.2025 | Draig Therapeutics Appoints Seasoned Neuroscience Leader Ivana Magovčević-Liebisch as President and Chief Executive Officer | • Dr Magovčević-Liebisch is an accomplished pharmaceutical and biotechnology executive with over 25 years of leadership experience • Dr Ruth McKernan FMedSci CBE, co-founder and Interim CEO, will continue as a Non-executive Director Cardiff... |
| 28.10.2025 | Sudo Biosciences Announces Positive Phase 1 Results for Brain-Penetrant Allosteric TYK2 Inhibitor SUDO-550 | CARMEL, Indiana & LONDON — Sudo Biosciences, (“Sudo”), a biopharmaceutical company committed to designing and developing best-in-class precision TYK2 (tyrosine kinase 2) inhibitors, today announced positive topline results from its Phas... |
| 27.10.2025 | Amphista Therapeutics’ successful degradation of a key cancer target, BRD9, via a novel mechanism with DCAF16 E3 ligase published in Nature Communications | Cambridge, UK, 27 October 2025 – Amphista Therapeutics (“the Company” or “Amphista”), a leader in next generation targeted protein degradation (TPD), announced today that it has published data in the journal Nature Communications demonstrat... |
| 15.10.2025 | Amphista Therapeutics nominates AMX-883, an orally available Targeted Glue™ degrader of BRD9, as its first clinical development candidate for the treatment of acute myeloid leukaemia | Cambridge, UK, 15 October, 2025 – Amphista Therapeutics (“the Company” or “Amphista”), a leader in the discovery of next generation Targeted Protein Degradation (TPD) medicines, announced today the nomination of AMX-883; a potent, selective... |
| 10.10.2025 | Prilenia and Ferrer to Share New Data and Analyses of Pridopidine’s Impact on Huntington’s Disease at the Huntington Study Group (HSG) Congress | Prilenia and Ferrer will present five posters at the 2025 HSG Huntington’s Disease (HD) Clinical Research Congress, including new analyses of 2-year data following patients not taking antidopaminergic medicines (ADMs) through both double-bl... |
| 09.10.2025 | AviadoBio and UgeneX Therapeutics Announce Exclusive Option-License Agreement to Develop Next Generation Optogenetics Gene Therapy to Restore Vision in Patients with Retinal Disease | LONDON, and SHANGHAI – October 9, 2025 – AviadoBio Ltd. (“AviadoBio”), and UgeneX Therapeutics, today announced an exclusive option and license agreement for the development and commercialization of UGX-202, an investigational, AAV-based ge... |
| 06.10.2025 | Harness Therapeutics Announces Launch of MISBA® Duo Platform and Research Collaboration with Ono Venture Investment | Cambridge, UK, 06 October 2025: Harness Therapeutics (‘Harness’), a biotechnology company unlocking previously undruggable targets to transform the treatment of neurodegenerative diseases, today announces the establishment of the second gen... |
| 06.10.2025 | Pridopidine Pivotal Phase 3 ALS Study Unveiled at NEALS 2025 Annual Meeting | Prilenia and Ferrer will unveil their planned pivotal Phase 3 study of pridopidine in ALS at the upcoming Northeast Amyotrophic Lateral Sclerosis Consortium (NEALS) 2025 Annual Meeting, Florida, October 7-10, 2025 Aimed at confirming the en... |
| 02.10.2025 | Sitryx receives FDA clearance of IND application for SYX-5219 for the treatment of atopic dermatitis | Oxford, UK and Boston, MA – 2 October 2025 – Sitryx Therapeutics (“the Company”), a clinical-stage biopharmaceutical company developing novel oral therapies to restore immune balance in autoimmune and inflammatory disease, today announces i... |
| 02.10.2025 | Draig Therapeutics Announces US FDA Clearance of IND Application for Phase 2 Study of DT-101 for the Treatment of Major Depressive Disorder | • DT-101 is designed to allow effective modulation of the AMPA receptor without compromising safety • Phase 2 clinical trial initiation anticipated before the end of 2025 • Trial builds on positive Phase 1 study that showed DT-101 was well ... |
| 24.09.2025 | Artios Receives U.S. FDA Fast Track Designation for alnodesertib in ATM-negative Metastatic Colorectal Cancer (mCRC) | CAMBRIDGE, United Kingdom and NEW YORK, September 24, 2025 – Artios Pharma Limited (“Artios”), a biopharmaceutical company committed to realizing the therapeutic power of targeting the DNA damage response (“DDR”) in cancer, today announced ... |
| 23.09.2025 | Amphista Therapeutics discloses first details of its TEAD Targeted Glue™ program and unveils new mechanism of action for TEAD degradation via FBXO22 | Amphista Therapeutics discloses first details of its TEAD Targeted Glue™ program and unveils new mechanism of action for TEAD degradation via FBXO22 Cambridge, UK, 23 September 2025 – Amphista Therapeutics (“the Company” or “Amphista”), a l... |
| 17.09.2025 | Amphista Therapeutics discloses first details of its SMARCA2 degrader program | Cambridge, UK, 17 September 2025 – Amphista Therapeutics (“the Company” or “Amphista”), a leader in the discovery of next generation targeted protein degradation (TPD) medicines, today disclosed first data on its SMARCA2 program including d... |
| 16.09.2025 | Dualitas Launches With $65 Million Series A to Advance Novel Bispecific Antibody Pipeline in Immune and Inflammatory Disease | - Versant Ventures and Qiming Venture Partners USA co-led financing with participation from founding investor SV Health Investors and new strategic investors Chugai Venture Fund, Eli Lilly and Company, and Alexandria Venture Investments - L... |
| 09.09.2025 | Alchemab Therapeutics initiates Phase 1 clinical trial of ATLX-1282 and announces Series A financing extension | Cambridge, UK, 9 September 2025 – Alchemab Therapeutics (Alchemab), a biopharmaceutical company which identifies and develops naturally occurring therapeutic antibodies from resilient individuals, today announced initiation of a Phase 1 fir... |
| 08.09.2025 | NRG Therapeutics Announces Oversubscribed £50m ($67m) Series B Financing to Deliver Clinical Data in Parkinson’s and Proof of Concept in ALS/MND | Stevenage, UK, 8 September 2025 - NRG Therapeutics Ltd. (“NRG”), an innovative neuroscience company targeting a novel mechanism to address mitochondrial dysfunction, is delighted to announce the closing of its oversubscribed £50m Series B f... |
| 05.09.2025 | Nature Medicine Publishes Phase 3 Data on Pridopidine in Early-Stage Huntington’s Disease, Highlighting Impact on Clinical Progression | Treatment with pridopidine slowed clinical progression and maintained function, cognition, and motor performance in pre-defined analyses of a subgroup of early-stage Huntington’s disease (HD) patients who were not taking antidopaminergic me... |
| 27.08.2025 | Leal Therapeutics Announces $30 Million Series A to Progress First-In-Class Neuro-Metabolic Therapies for Neurodegenerative and Neuropsychiatric Disorders with High-Unmet Need | WORCESTER, Mass., Aug. 27, 2025 / PRNewswire / - Leal Therapeutics, Inc., a biotechnology company developing novel therapeutics for patients with disorders of the central nervous system (CNS), today announced a $30 million Series A financin... |
| 12.08.2025 | Artios Pharma Appoints Michael T. Andriole as CEO and Director to Advance Alnodesertib (ART0380) into Late-stage Development | CAMBRIDGE, United Kingdom and NEW YORK, August 12, 2025 – Artios Pharma Limited (“Artios”), a biopharmaceutical company committed to realizing the therapeutic power of targeting the DNA damage response (“DDR”) in cancer, today announced the... |
| 29.07.2025 | Therini Bio Announces First Patient Dosed in Phase 1b Trial of THN391 in Alzheimer’s Disease | Sacramento, July 29, 2025 (GLOBE NEWSWIRE) - Therini Bio, Inc., a clinical-stage biotech company developing fibrin-targeting immunotherapies for neurodegenerative diseases driven by vascular dysfunction today announced that the first patien... |
| 21.07.2025 | The UK needs to pick up the pace on life sciences | The UK’s Life Sciences Sector Plan may be bold — but it’s destined to disappoint unless we pick up the pace. It sets out 33 government-backed actions to ensure the UK becomes Europe’s leading life sciences economy by the end of this decade,... |
| 16.07.2025 | Amphista Therapeutics announces achievement of a research milestone in its collaboration with Merck triggering a milestone payment | Cambridge, UK, 16 July 2025 – Amphista Therapeutics (“the Company” or “Amphista”), a leader in the discovery of next-generation, Targeted Protein Degradation (TPD) medicines, today announces the successful achievement of a discovery researc... |
| 14.07.2025 | SV is hiring: Associate – Dementia Discovery Fund | Position Title: Associate - Dementia Discovery Fund Location: Boston Office Effective Date: Immediate Compensation: Competitive About the Opportunity SV Health Investors’ Dementia Discovery Fund (DDF) is seeking an ambitious and driven Asso... |
| 23.06.2025 | Biotech is coming to Wales: A new biotech organisation is eschewing more established innovation centres for Cardiff. Why? | In 2010 Simon Ward, an associate director in the neuroscience division at the pharmaceutical firm Glaxo-Smith Kline (GSK), was fired, along with the rest of the division. At the time, the guillotining of neuroscience was part of a global mo... |
| 18.06.2025 | Welsh biotech wins funding to develop new depression treatments | $140mn financing will allow Draig Therapeutics to move drug candidates into .. |
| 18.06.2025 | Draig Therapeutics Launches with $140 Million (£107 Million) Total Investment to Advance its Portfolio of Next-Generation Therapies for Major Neuropsychiatric Disorders | Cardiff, United Kingdom – 18 June 2025 – Draig Therapeutics (“Draig”), a clinical-stage company aiming to transform the treatment of neuropsychiatric diseases, today launches from stealth having raised a total of $140 million (£107 million)... |
| 16.06.2025 | Kate Bingham quoted in 'UK patients to gain direct access to clinical trials, says Wes Streeting' | Expansion of NHS app comes as part of government’s 10-year plan for health service |
| 13.06.2025 | Guardian Article 'Transformative’: the UK lab working on a way to halt genetic type of dementia | AviadoBio’s breakthrough therapy hopes to stop progress of FTD, which is usually diagnosed in people under 65 |
| 10.06.2025 | Quell Therapeutics Achieves Key Milestone in its CAR-Treg Cell Therapy Program for Inflammatory Bowel Disease | London, UK – 10 June, 2025 – Quell Therapeutics Ltd (“Quell”), a leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, announces that AstraZeneca has selected a lead T... |
| 29.05.2025 | Alzheimer’s Association Fuels Global Treatment Breakthroughs with $10M Venture Fund Investment | CHICAGO, MAY 29, 2025 — The Alzheimer’s Association announced a strategic investment of $10 million (~€8.94 million) in the Dementia Discovery Fund 2 (DDF-2), part of the world’s largest family of specialized venture capital funds exclusive... |
| 28.05.2025 | Transposon Announces TPN-101 Selected for Inclusion in the Phase 2/3 HEALEY ALS Platform Trial, Building on the Success of Phase 2 Study in C9orf72-related ALS | In the Phase 2 Study of TPN-101 in patients with C9orf72-related ALS, TPN-101 showed clinical benefits on key clinical outcome measures, including slow vital capacity and the ALSFRS-R TPN-101 also had lowering effects on key biomarkers of n... |
| 21.05.2025 | Montara Therapeutics to Develop Novel Treatments Using the BrainOnly™ Platform with Grant from The Michael J. Fox Foundation | SAN FRANCISCO, May 21, 2025 (GLOBE NEWSWIRE) -- Montara Therapeutics, a biotech company pioneering brain-selective therapies for central nervous system (CNS) diseases, today announced it has received a research grant from The Michael J. Fox... |
| 20.05.2025 | SV Health Investors’ Dementia Discovery Fund Announces $269m Final Close of DDF-2 | Leading transatlantic venture capital fund to continue its successful investment strategy focused on dementia LONDON/BOSTON – May 20th 2025. The Dementia Discovery Fund (“DDF”), managed by SV Health Investors, today announced the final clos... |
| 19.05.2025 | Alchemab Therapeutics on BiotechTV | Alchemab Therapeutics Ltd last week signed a second collaboration with Eli Lilly worth up to $415M to license its IND ready program for ALS and other neurodegenerative diseases. CEO Jane Osbourn OBE describes Alchemab's platform, which look... |
| 15.05.2025 | Quiver Bioscience and QurAlis Announce Research Collaboration to Advance Novel Therapeutic Approach for Fragile X Syndrome | CAMBRIDGE, Mass. – May 15, 2025 – Quiver Bioscience (“Quiver”) and QurAlis Corporation (“QurAlis”), today announced that the companies have entered into a research collaboration to advance a novel gene-targeted therapeutic approach for the ... |
| 15.05.2025 | QurAlis Announces Exclusive License on Novel Mechanism for Fragile X Syndrome (FXS) to Enable Development of First Potential Disease-Modifying Therapy | CAMBRIDGE, Mass., May 15, 2025 – QurAlis Corporation (“QurAlis”), a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that have the potential to alter the trajectory of neurodegenerative... |
| 15.05.2025 | AviadoBio Announces ASPIRE-FTD Phase 1/2 Clinical Trial in the UK at Cambridge University Hospitals NHS Foundation Trust, Cardiff and Vale University Health Board, and University College London | LONDON – May 15, 2025 – AviadoBio, a pioneering gene therapy company dedicated to developing and delivering potentially transformative medicines for neurodegenerative disorders, today announced that its Phase 1/2 ASPIRE-FTD clinical trial i... |
| 14.05.2025 | Therini Bio Raises Additional $39M Series A Financing to Advance Clinical Development of Neurodegenerative Disease Pipeline | Sacramento, May 14, 2025 (GLOBE NEWSWIRE) - Therini Bio, Inc., a clinical-stage biotech company developing fibrin-targeting immunotherapies for neurodegenerative diseases driven by vascular dysfunction today announced that it raised $39 mil... |
| 13.05.2025 | Packaging Compliance Labs Completes Acquisition of Quest Engineering Solutions, Expands Testing Capabilities and East Coast Presence | GRAND RAPIDS, Mich., May 13, 2025 /PRNewswire/ -- Packaging Compliance Labs (PCL), an industry leader in sterile packaging solutions for the medical device and life sciences markets, today announced the acquisition of Quest Engineering Solu... |
| 06.05.2025 | Alchemab Therapeutics signs landmark $415m licensing agreement for ATLX-1282 with Eli Lilly and Company | Cambridge, UK, 6 May 2025 – Alchemab Therapeutics (Alchemab), the next generation biopharmaceutical company which uses the power of human immune evolution to identify and develop naturally occurring therapeutic antibodies from resilient ind... |
| 06.05.2025 | Sitryx nominates SIT-047, a novel, oral MTHFD2 inhibitor, for clinical development in psoriatic arthritis | Oxford, UK – 6 May 2025 – Sitryx Therapeutics (“the Company”), a clinical-stage biopharmaceutical company developing novel oral therapies to restore immune balance in autoimmune and inflammatory disease, today announces the nomination of SI... |
| 02.05.2025 | SUN Behavioral Health Acquires Seaside’s Community Agencies, Expanding Access to Community-Based Mental Health Services Across the Southeast | May 2, 2025 – SUN Behavioral Health, a leading provider of inpatient and outpatient psychiatric services, today announced the acquisition of the home- and community-based services division of Seaside Healthcare, a prominent behavioral healt... |
| 01.05.2025 | AviadoBio Announces Completion of Second Cohort in Phase 1/2 ASPIRE-FTD Clinical Trial Studying AVB-101 for FTD-GRN | LONDON — MAY 1, 2025 — AviadoBio, a pioneering gene therapy company dedicated to developing and delivering potentially transformative medicines for neurodegenerative disorders, today announced the completion of the second dose cohort in its... |
| 29.04.2025 | Artios Pharma Reports Differentiated Clinical Activity in STELLA Phase 1/2a Study for Lead Program ART0380 at the American Association for Cancer Research (AACR) Annual Meeting 2025 | CAMBRIDGE, United Kingdom and NEW YORK, April 29, 2025 – Artios Pharma Limited (“Artios”), a clinical-stage biotech company led by pioneers of DNA damage response (“DDR”) drug development, today reported encouraging data from its ongoing ST... |
Show more
Mentions in press and media 103
| Date | Title | Description |
| 17.08.2026 | Leal Therapeutics Raises $30M in Second Close of Series A Funding | Leal Therapeutics, a Worcester, MA-based provider of neuro-metabolic therapeutics for central nervous system disorders, raised $30M in the second close of its Series A funding. Backers included Eli Lilly and Company, OrbiMed, Newpath Partne... |
| 16.07.2026 | AdvanCell Closes $315 Million Series D | BOSTON, MA, AdvanCell, a clinical-stage radiopharmaceutical company, announced the closing of an oversubscribed and upsized $315 million Series D financing. >> Click here for more funding data on AdvanCell >> To export AdvanCel... |
| 15.07.2026 | AdvanCell Closes US $315M in Series D Funding | AdvanCell, a Boston, MA- and Brisbane, Australia-based clinical-stage radiopharmaceutical company developing targeted alpha therapies for cancer, raised US $315M Series D in funding. The round was led by Ally Bridge Group and Alpha Wave, al... |
| 15.07.2026 | AdvanCell Closes $315 Million Series D Financing To Advance Targeted Alpha Therapies | AdvanCell, a clinical-stage radiopharmaceutical company developing targeted alpha therapies for cancer, announced the closing of an oversubscribed and upsized $315 million Series D financing. The round was led by Ally Bridge Group and co-le... |
| 14.07.2026 | Draig Therapeutics Raises $65 Million Series B To Advance Neuropsychiatric Therapies | Draig Therapeutics announced the closing of an oversubscribed $65 million Series B financing to accelerate development of its pipeline of neuropsychiatric therapies. The round was led by new investor Deep Track Capital, with participation f... |
| 14.07.2026 | Draig Therapeutics Closes $65 Million Series B To Advance AMPA And GABAA Receptor Modulators In Neuropsychiatric Disorders | Draig Therapeutics, a clinical-stage biopharmaceutical company co-founded by Cardiff University and SV Health Investors and headquartered across Newton, Massachusetts and Cardiff, United Kingdom, has closed an oversubscribed $65 million Ser... |
| 11.07.2026 | Alchemab Secures £25M Series A Extension, Fuels AI-Driven Antibody Pipeline | Alchemab Therapeutics landed a substantial £25M Series A extension. The British Business Bank led this pivotal investment. It pushes Alchemab's total Series A funding to an impressive £109M. This capital injection accelerates the Cambridge,... |
| 10.07.2026 | Alchemab Therapeutics Extends Series A Financing with USD34M | Alchemab Therapeutics, a Cambridge, UK-based clinical-stage biotechnology company, raised £25M (USD$34M) in Series A extension funding from British Business Bank. Current investors included SV Health Investors and the Dementia Discovery Fun... |
| 09.07.2026 | Alchemab Raises £25 Million Extension to Series A to Advance AI-Driven Antibody Pipeline | Clinical-stage biotechnology company Alchemab Therapeutics announced a £25 million (approximately $34 million) extension to its Series A financing from the British Business Bank. The investment marks the largest life sciences investment mad... |
| 15.05.2026 | EBT Medical and NinaMED Announce US$13.75M Financing to Advance Licensed NiNA System® for Overactive Bladder | The NiNA System® is not approved for sale or commercial use in the United States, Canada or Australia. The Nina System® is a registered trademark of EBT Medical, Inc. in Canada. About EBT Medical, Inc.EBT Medical is the originator and licen... |
| 14.05.2026 | EBT Medical and NinaMED Announce US$13.75M Financing to Advance Licensed NiNA System® for Overactive Bladder | US$13.75M financing completed to accelerate clinical pathway and global commercialisation Establishment of NinaMED Pty Ltd, a new Australian medtech company NinaMED Pty Ltd secures a license from EBT Medical for exclusive global rights to N... |
| 12.05.2026 | Cerevance Completes Enrollment in Pivotal Phase 3 Parkinson’s Disease Trial and Closes Oversubscribed $20 Million Series C to Extend Runway into 2027 | Boston – MAY 12, 2026 – Cerevance, a clinical-stage biopharmaceutical company advancing targeted therapies for neurodegenerative diseases and obesity, today announced completion of patient enrollment in the pivotal Phase 3 ARISE trial evalu... |
| 06.04.2026 | Versant Media Group Acquires StockStory | Versant Media Group, Inc. (NASDAQ: VSNT) acquired StockStory, a Middletown, DE-based AI-powered platform delivering financial analysis, market insights, and stock recommendations. The acquisition enables Versant’s continued expansion of its... |
| 06.04.2026 | EpiVax Receives Investment from SV Health Investors | SV Health Investors, a healthcare and life sciences focused private equity firm, made an investment in EpiVax, Inc., a Providence, RI-based bioanalytical CRO specializing in immunogenicity risk assessments for pharmaceutical and biotech com... |
| 21.03.2026 | Biotech Powerhouse Mestag Therapeutics Secures $40M for Advanced Therapies | Mestag Therapeutics has secured $40 million in new financing. This pushes its total funding past $95 million. The Cambridge-based biotech fuels its Phase 1 STARLYS clinical trial for cancer drug MST-0312. This pivotal trial begins in mid-20... |
| 17.03.2026 | Mestag Therapeutics: $40 Million Raised To Advance Fibroblast Immunology Cancer Therapies Into Clinic | Mestag Therapeutics, a biotech company focused on fibroblast immunology, has announced the closing of a $40 million financing round, bringing its total funding to more than $95 million. The round was backed by SV Health Investors, Johnson &... |
| 17.03.2026 | Mestag Therapeutics Raises $40M in Financing | Mestag Therapeutics, a Cambridge, UK-based biotech company harnessing fibroblast immunology to develop treatments for cancer and inflammatory diseases, closed a $40m financing. Backers includwed SV Health Investors, Johnson & Johnson, t... |
| 31.01.2026 | TRexBio Secures $50M to Accelerate Treg-Targeted Immunotherapy Pipeline | TRexBio secured $50 million. This clinical-stage biotech develops precision immunoregulatory medicines. Its focus: tissue regulatory T cell (Treg) biology. Funding fuels clinical and preclinical pipeline advancement. Lead program TRB 061, a... |
| 28.01.2026 | TRexBio: $50 Million Raised To Advance Tissue-Targeted Treg Immunology Pipeline | TRex Bio, a clinical-stage biotechnology company focused on precision immunoregulatory medicines derived from tissue regulatory T cell biology, announced it closed an oversubscribed $50 million financing to support clinical and preclinical ... |
| 27.01.2026 | TRexBio Raises $50M in Funding | TRexBio, a San Francisco, CA-based clinical-stage biotechnology company, raised $50M in funding. Backers included new investors Janus Henderson Investors, Balyasny Asset Management L.P. and Affinity Asset Advisors, as well as existing inves... |
| 20.01.2026 | SV Health Investors Appoints Miles Gerson as Partner | Former Head of Takeda Ventures to Co‑Lead the Dementia Discovery Funds and Expand U.S. Investment Activities London and Boston, 9 January 2026 – SV Health Investors ("SV") today announced the appointment of Miles Gerson as Partner... |
| 13.01.2026 | HPS/PayMedix Secures $33 Million Investment | MILWAUKEE, Jan. 13, 2026 /PRNewswire/ -- HPS/PayMedix, the leading healthcare financing and payments solutions provider, today announced it has closed $33 million in equity and debt financing to accelerate the growth of its groundbreaking P... |
| 13.01.2026 | HPS/PayMedix Secures $33 Million Investment To Expand Healthcare Financing Platform | HPS/PayMedix announced it has closed $33 million in combined equity and debt financing to accelerate national growth of PayMedix, its healthcare financing and payments platform designed to simplify how consumers and providers manage medical... |
| 13.01.2026 | HPS/PayMedix Raises $33M in Equity and Debt Financing | HPS/PayMedix, a Milwaukee, WI-based healthcare financing and payments solutions provider, raised $33M in equity and debt financing. HLM Investment Partners, led a $16M growth equity investment with participation from Escalate Capital Partne... |
| 06.01.2026 | LoQus23 Therapeutics nominates LQT-23 as first-in-class, oral drug candidate for Huntington’s Disease | Cambridge, UK, 6 January 2026 – LoQus23 Therapeutics Ltd (“LoQus23”), a biotechnology company investigating small molecule drugs that could stop the pathogenic triplet expansion that is the cause and driver of Huntington’s Disease (HD), myo... |
| 02.12.2025 | TRIMTECH Therapeutics appoints Alison Lawton as Chair of the Board | Cambridge, UK, 2 December 2025: TRIMTECH Therapeutics, a biotechnology company developing novel small molecule therapies that target and degrade protein aggregates associated with neurodegenerative diseases, today announced the appointment ... |
| 19.11.2025 | Artios Pharma Secures $115M to Advance Cancer Therapies | Artios Pharma, a UK-based biotech firm, has secured $115 million in Series D funding. The financing aims to boost the development of its precision cancer treatments. Focus on DNA damage response (DDR) is key. Funds will advance clinical tri... |
| 17.11.2025 | €99 million Series D fuels Artios’ expansion of precision cancer treatment pipeline | Artios Pharma Limited, a British biopharmaceutical company committed to realising the therapeutic potential of targeting the DNA damage response (DDR) in cancer, today announced the successful close of an oversubscribed €99 million ($115 mi... |
| 17.11.2025 | Artios raises $115M Series D to accelerate first-in-class cancer therapies | Biotech company Artios today announced the successful close of an oversubscribed $115 million Series D financing. Artios is pioneering next-generation approaches in the DNA damage response (DDR) field through its comprehensive anti-cancer a... |
| 09.09.2025 | Alchemab Therapeutics initiates Phase 1 clinical trial of ATLX-1282 and announces Series A financing extension | Cambridge, UK, 9 September 2025 – Alchemab Therapeutics (Alchemab), a biopharmaceutical company which identifies and develops naturally occurring therapeutic antibodies from resilient individuals, today announced initiation of a Phase 1 fir... |
| 09.09.2025 | Alchemab Therapeutics Raises Series A Extension Financing | Alchemab Therapeutics, a London, UK-based biopharmaceutical company which identifies and develops naturally occurring therapeutic antibodies from resilient individuals, raised an undisclosed amount in Series A extension funding. Backers inc... |
| 08.09.2025 | NRG Therapeutics Secures £50M to Advance Neurodegenerative Disease Therapies | NRG Therapeutics just closed a monumental £50 million Series B financing. This oversubscribed round fuels vital neurodegenerative disease research. The UK-based firm targets mitochondrial dysfunction. Its lead program, NRG5051, aims to trea... |
| 08.09.2025 | NRG Therapeutics secures £50M Series B to advance mitochondrial drugs for ALS and Parkinson’s | Stevenage-based biotech startup NRG Therapeutics has closed a £50 million Series B funding round as it moves towards clinical trials for its pipeline of treatments targeting mitochondrial dysfunction in neurodegenerative diseases. The round... |
| 08.09.2025 | NRG Therapeutics Announces Oversubscribed £50m ($67m) Series B Financing to Deliver Clinical Data in Parkinson’s and Proof of Concept in ALS/MND | Stevenage, UK, 8 September 2025 – NRG Therapeutics Ltd. (“NRG”), an innovative neuroscience company targeting a novel mechanism to address mitochondrial dysfunction, is delighted to announce the closing of its oversubscribed £50m Series B ... |
| 08.09.2025 | NRG Therapeutics Announces Oversubscribed £50m ($67m) Series B Financing to Deliver Clinical Data in Parkinson’s and Proof of Concept in ALS/MND | Stevenage, UK, 8 September 2025 - NRG Therapeutics Ltd. (“NRG”), an innovative neuroscience company targeting a novel mechanism to address mitochondrial dysfunction, is delighted to announce the closing of its oversubscribed £50m Series B f... |
| 30.08.2025 | Leal Therapeutics: $30 Million Series A Secured To Advance Breakthrough CNS Therapies | Leal Therapeutics, a biotechnology company pioneering novel treatments for central nervous system (CNS) disorders, has announced the closing of a $30 million Series A financing round. The round was led by SV Health Investors’ Dementia Disco... |
| 27.08.2025 | Leal Therapeutics Raises $30M in Series A Funding | Leal Therapeutics, a Worcester, MA-based biotechnology company developing novel therapeutics for patients with disorders of the central nervous system (CNS), raised $30M in Series A funding. The round was led by SV Health Investors’ Dementi... |
| 27.05.2025 | SV Health Investors beats target for dementia-focused fund | - |
| 20.05.2025 | SV Health’s latest pharma-backed dementia fund raises $269M to invest in new therapies | A dementia-focused transatlantic venture capital initiative has secured $269 million in commitments for its second fund. The first Dementia Discovery Fund (DDF) was launched by VC firm SV Health Investors a decade ago with the goal of deliv... |
| 20.05.2025 | SV Health Investors’ Dementia Discovery Fund Announces $269m Final Close of DDF-2 | Leading transatlantic venture capital fund to continue its successful investment strategy focused on dementia LONDON/BOSTON – May 20th 2025. The Dementia Discovery Fund (“DDF”), managed by SV Health Investors, today announced the final clos... |
| 17.05.2025 | Therini Bio Secures $39 Million to Combat Neurodegenerative Diseases | In the ever-evolving landscape of biotechnology, Therini Bio, Inc. has made headlines by securing an additional $39 million in Series A financing. This funding is a beacon of hope for those grappling with neurodegenerative diseases. Based i... |
| 15.05.2025 | Therini Bio Raises Additional $39M in Series A Financing | Therini Bio, Inc., a Sacramento, CA-based clinical-stage biotech company developing fibrin-targeting immunotherapies for neurodegenerative diseases driven by vascular dysfunction raised $39m in Series A extension financing. The extension fi... |
| 24.04.2025 | Centauri Health Solutions Acquires MedAllies | Centauri Health Solutions, a Phoenix, AZ-based health information technology company, acquired MedAllies, a New York-based health information service provider (HISP) and qualified health information network (QHIN) company. The amount of the... |
| 11.04.2025 | Imbria Pharmaceuticals: A New Dawn in Cardiometabolic Treatment | Imbria Pharmaceuticals is on the rise. The Boston-based biotech company recently secured $57.5 million in a Series B financing round. This funding is a lifeline, aimed at advancing their promising drug, ninerafaxstat, for treating non-obstr... |
| 11.04.2025 | Imbria Pharmaceuticals Raises $57.5M in Series B Financing | Imbria Pharmaceuticals, Inc., a Boston, MA-based clinical stage biotechnology company developing novel therapies for cardiometabolic diseases with high unmet need, closed a $57.5m Series B financing. The round was led by new investor, Deep ... |
| 20.03.2025 | British investment firm secures $250M to help fund development of new dementia therapeutics | British investment firm SV Health Investors has secured $250 million to go toward the development of first-in-class therapeutics for dementia, the second such fund the venture capitalists have put together. The final push past the finish li... |
| 20.03.2025 | British Patient Capital announces £25m commitment to SV Health Investors’ Dementia Discovery Fund 2 | London, 20 March 2025: British Patient Capital, a commercial subsidiary of the British Business Bank, has made a £25 million commitment to the Dementia Discovery Fund 2 (DDF-2), managed by SV Health Investors. This follows British Patient C... |
| 15.03.2025 | Perfuze: €22 Million Raised And Clearance Received For Zipline Access Catheters | Perfuze, a leading medical device company dedicated to advancing stroke treatment, has received FDA 510(k) clearance for its Zipline Access Catheters. This milestone strengthens Perfuze’s growing portfolio of innovative neurovascular device... |
| 13.03.2025 | Perfuze Raises €22M in Additional Funding | Perfuze, a Galway, Ireland-based medical device company, raised €22M in additional funding. The round was led by existing investors including Earlybird, EQT Life Sciences, Seroba and SV Health. Led by CEO Wayne Allen, Perfuze is a medical d... |
| 11.03.2025 | Ria Health: Growth Capital Raised To Advance Access To AUD Treatment | Ria Health – a leading telehealth provider of evidence-based alcohol use disorder (AUD) treatment – announced the closing of a Series B growth equity round led by Peloton Equity, with participation from existing investors including SV Healt... |
| 07.03.2025 | TRIMTECH Therapeutics: A New Dawn in Neurodegenerative Disease Treatment | In the heart of Cambridge, a biotech revolution is brewing. TRIMTECH Therapeutics has emerged as a beacon of hope for those grappling with neurodegenerative diseases. With a recent funding boost of €28.6 million, the company is poised to ta... |
| 06.03.2025 | TRIMTECH Therapeutics raises €28.6 million for treatment of neurodegenerative diseases | Cambridge-based TRIMTECH Therapeutics, a BioTech company harnessing targeted protein degradation (TPD) for the treatment of neurodegenerative diseases, announced the closing of its €28.6 million Seed funding round. The financing was led by ... |
| 06.03.2025 | Ria Health Raises Growth Funding | Ria Health, a Greenwich, CT-based telehealth provider of evidence-based alcohol use disorder (AUD) treatment, raised an undisclosed amount in funding. The round was led by Peloton Equity, with participation from existing investors including... |
| 10.02.2025 | AdvanCell Successfully Completes an Oversubscribed US$112M Series C Financing | Sydney, Australia – 3 February 2025 – AdvanCell, a clinical-stage radiopharmaceutical company developing innovative cancer therapeutics, today announced the successful completion of an oversubscribed US$112 million Series C financing. This ... |
| 27.12.2024 | SV Health Investors: A.J. Rossi Promoted To Partner | SV Health Investors – a leading healthcare-focused private equity firm – announced the promotion of A.J. Rossi to Partner on the firm’s Growth-Buyout team. In this new role, A.J. will continue to lead investments and manage the SV portfolio... |
| 23.11.2024 | TRexBio: $84 Million (Series B) Closed To Decode Human Tissue Immune Biology | TRex Bio – a biotechnology company decoding human tissue immune biology to create revolutionary therapeutics – announced the closing of an oversubscribed $84 million Series B funding round. This funding was led by Delos Capital, with additi... |
| 30.10.2024 | Seasoned Healthcare Executive Jim Costanzo Joins Innovative Board of Directors | Jim Costanzo Jim Costanzo, former Nordic CEO, joins Innovative’s Board, bringing 40 years of visionary expertise to drive strategic growth and healthcare IT excellence. Jim is a true strategist with an impressive track record of successfull... |
| 13.09.2024 | SpectraWAVE: $50 Million (Series B) Raised To Advance HyperVue Imaging System | SpectraWAVE., a medical imaging company focused on improving the treatment and outcomes for patients with coronary artery disease (CAD), announced a $50 million Series B funding round led by Johnson & Johnson Innovation – JJDC and joine... |
| 11.09.2024 | SpectraWAVE Raises $50M in Series B Financing | SpectraWAVE, Inc., a Bedford, MA-based medical imaging company focused on improving the treatment and outcomes for patients with coronary artery disease (CAD), raised $50M in Series B funding. The round was led by Johnson & Johnson Inno... |
| 10.09.2024 | CSA Medical's $53 Million Boost: A Breath of Fresh Air for Chronic Bronchitis Treatment | In the bustling world of medical innovation, CSA Medical has just made waves. The Boston-based company recently secured $53 million in Series D funding. This investment is not just a number; it represents hope for countless patients sufferi... |
| 09.09.2024 | CSA Medical: $53 Million (Series D) Raised For Advancing RejuvenAir System | CSA Medical, the developer of The RejuvenAir System (a Breakthrough Medical Device advancing the power of liquid nitrogen spray cryotherapy for the treatment of chronic bronchitis), announced the completion of an oversubscribed $53 million ... |
| 09.09.2024 | CSA Medical Raises $53M in Series D Financing | RejuvenAir Metered Cryospray CSA Medical, a Boston, Ma-based developer of The RejuvenAir® System, a medical device advancing liquid nitrogen spray cryotherapy for the treatment of chronic bronchitis, raised $53M in Series D funding. The rou... |
| 12.08.2024 | Spineology: Medical Device Company Raises $25 Million (Series AA) | Spineology, a medical device company pioneering Conform and Expand spinal fusion technology, announced that it has raised $25 million in Series AA financing led by SV Health Investors, with participation from 1315 Capital and its existing i... |
| 21.05.2024 | Innovative Consulting Group Appoints Peter Witonsky as Chief Revenue Officer | Proven Executive with Strong Record of Success to Lead Sales Efforts PANAMA CITY, FLORIDA, UNITED STATES, May 21, 2024 /EINPresswire.com/ -- Innovative Consulting Group, a healthcare IT consulting firm that delivers flexible solutions and n... |
| 22.03.2024 | 35% of Northern Ireland's funding deals went to women-led startups last year | 65 per cent of Northern Ireland's 72 funding deals last year went to startups with all-male executive teams, according to Catalyst’s Deal Tracker. Of all companies who received funding, 35 per cent had at least one female executive whilst z... |
| 12.03.2024 | Prilenia Plans to Submit Marketing Authorization Application (MAA) in the EU for Pridopidine in Huntington’s Disease | NAARDEN, Netherlands & WALTHAM, Mass.--(BUSINESS WIRE)-- Prilenia Therapeutics B.V., a clinical stage biotechnology company focused on the urgent mission to develop novel therapeutics to slow the progression of neurodegenerative disease... |
| 16.10.2023 | AstronauTx, developing treatments for Alzheimer's, raises $59M Series A | The startup works in partnership with UCL and is backed by Novartis and UK gov't funds In the United States alone, about 10.7% of people age 65 and older are living with Alzheimer's – the most common form of dementia. That number is project... |
| 10.08.2022 | Femtech Startup Nanopath Raises $10M to Develop POC Diagnostics for Women’s Health | What You Should Know: Nanopath Co-Founders Dr. Amogha Tadimety (Left) and Dr. Alison Burklund (Right) Founded by Dr. Amogha Tadimety and Dr. Alison Burklund to address disparities in women’s health and with a platform that is designed to be... |
| 20.01.2022 | POLPHARMA WANTS TO TEAM UP WITH PRIVATE EQUITY INVESTORS TO FUND ZENTIVA BID VALUED AT UP TO 3.5 BLN EUROS - SOURCES | POLPHARMA WANTS TO TEAM UP WITH PRIVATE EQUITY INVESTORS TO FUND ZENTIVA BID VALUED AT UP TO 3.5 BLN EUROS - SOURCES |
| 29.11.2021 | Syncona : Quell Therapeutics Raises $156 million in Oversubscribed Series B Financing to Advance its Pioneering Multi-Modular Engineered T Regulatory (Treg) Cell Therapy Pipeline and Platform | - Series B co-led by Jeito Capital, Ridgeback Capital Investments, SV Health Investors and Fidelity Management & Research Company LLC, alongside founding investor Syncona and includes a broad syndicate of international life science focu... |
| 19.08.2021 | SV Health : Investors Announces Three Realizations in its Growth Equity Portfolio | BOSTON, Aug. 19, 2021 /PRNewswire/ -- SV Health Investors ("SV"), a leading global health care investment firm, is pleased to announce a series of realizations from its growth equity portfolio: On August 6, HillRom (NYSE: HRC) com... |
| 02.06.2021 | Transine Therapeutics closes extended seed funding of £9.1m to advance its novel class of therapeutic RNAs | Transine Therapeutics closes extended seed funding of £9.1m to advance its novel class of therapeutic RNAs 02-06-2021 New company emerges from stealth with potential ground-breaking mRNA therapeutic platform to increase protein expression. ... |
| 02.06.2021 | Transine Therapeutics closes extended seed funding of £9.1m to advance its novel class of therapeutic RNAs | New company emerges from stealth with potential ground-breaking mRNA therapeutic platform to increase protein expression. Transine Therapeutics, a biotechnology company developing a novel class of therapeutic RNAs based on its pioneering SI... |
| 01.06.2021 | NATIONAL HEALTH INVESTORS, INC. National Health Investors : NHI Announces $62.3 Million Investment in Specialty Behavioral Health | MURFREESBORO, TN / ACCESSWIRE / June 1, 2021 / National Health Investors, Inc. (NYSE:NHI) announced today that it has invested $40.3 million for the acquisition of Brookhaven Hospital, a specialty behavioral health hospital in Tulsa, OK. Br... |
| 11.09.2020 | GSK and J&J alum Vijay Reddy to take control of R&D at Tmunity; Andrew Hirsch exits Agios for CEO job at C4 Therapeutics | Vijay Reddy → Vijay Reddy was seeking a return to the US when he left his role as CMO at London-based Autolus this summer. Philadelphia is that landing spot, as the T cell immunotherapy player Tmunity has put him in charge... |
| 02.07.2020 | Evidation Health Lands $45M to Expand into Virtual Health Market, Appoints Chief Commercial Officer | What You Should Know: – Evidation Health raises $45M in Series D funding to expand its privacy-first, direct-to-person research platform to the virtual health market. – Evidation Health will use this new investment to enable Achievers to ga... |
| 04.03.2020 | SV Health Investors joins Xilio Therapeutics’ $100.5 million Series B financing - proceeds will advance XTX201 and XTX101 into the clinic while expanding Xilio’s cytokine pipeline | SV Health Investors join existing investors F-Prime Capital and Atlas Venture alongside other new investors, including the strategic venture capital arms of Takeda, Merck & Co, and EMD Serono |
| 19.02.2020 | Endotronix Enrolls First Patients in PROACTIVE-HF Pivotal Trial | LISLE, Ill. /PRNewswire/ — Endotronix, a digital health and medical technology company dedicated to advancing the treatment of chronic heart failure (HF), today announced the enrollment of the first two patients in the PROACTIVE-HF pivotal ... |
| 09.01.2020 | Abry to Take Majority Stake in Centauri | Centauri Health Solutions, Inc., an innovative provider of healthcare technology and services, today announced an agreement under which Abry Partners will acquire a majority stake in Centauri. With this transaction, Abry, one of the premier... |
| 05.11.2019 | Healthify Raises $16M to Integrate Health and Social Services | The latest funding marks a pivotal point in the movement toward value-based care |
| 04.11.2019 | Healthify Raises $16M Series B | NEW YORK, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Healthify, the leading company integrating the social determinants of health (SDoH) in the era of value-based healthcare, has raised $16 million in a Series B financing round led by SV Health Inve... |
| 14.10.2019 | Top 10 VCs investing in medical device companies | They include NEA, Versant Ventures, SOSV and Innova Memphis Healthtech is a big and broad space, so much so that there are whole subsectors that see more investments than entire industries. Medical device companies, for example, raised $2.9... |
| 01.10.2019 | Endotronix Closes Expanded Series D Financing Round of $70 Million for Heart Failure Solution | LISLE, IL – Endotronix, Inc., a digital health, medtech company dedicated to advancing the treatment of heart failure (HF), today announced the expansion of its Series D financing round, bringing the total for the round to $70 million. The ... |
| 26.11.2018 | Rheostat Therapeutics Raises $23M Series A | CAMBRIDGE, Mass., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Rheostat Therapeutics, a biotech company focused on the discovery of novel treatments for neurodegeneration, cognition and rare diseases, today announced the close of a Series A financing ... |
| 14.09.2018 | Endotronix Raises $45 Million in Series D Financing for the Treatment of Heart Failure | Endotronix, Inc., a digital health, medtech company dedicated to advancing the treatment of heart failure, today announced the close of a Series D financing round totaling $45 million. The round was led by LSP, investing from its LSP Health... |
| 25.06.2018 | The Dementia Discovery Fund Raises $350M | The Dementia Discovery Fund (DDF), a Boston, MA and London, UK-based venture capital fund focused on discovering and developing novel therapies for dementia, including Alzheimer’s disease, completed its fundraising, with $350m (£250m) raise... |
| 25.06.2018 | AARP commits $60 million to a fund backing new treatments for dementia | Dementia, the syndrome caused by several brain illnesses affecting memory, motor skills, thinking and behavior, affects 47 million people around the world and is projected to afflict 75 million by 2030, according to the World Health Organiz... |
| 25.06.2018 | AARP Invests $60M in the Dementia Discovery Fund | With nearly 10 million new cases of dementia and Alzheimer's disease occurring each year1, and no cure, today AARP launched a new campaign, "Disrupt Dementia." The campaign aims to help drive new diagnostics and treatments for dem... |
| 25.06.2018 | AARP invests $60M in Dementia Discovery Fund | AARP has shown it’s interested in tech, bringing startups to its D.C. incubator and virtual reality to local events. Now the D.C.–based org is getting involved in venture. On Monday, AARP announced a $60 million investment in a fund which i... |
| 25.06.2018 | The Dementia Discovery Fund Raises $350 Million | Includes $60 million new investment from US AARP |
| 17.01.2018 | SV Health Investors Announces Two Promotions Within Financial Team | SV Health Investors, a Boston, MA-based venture capital and growth equity firm, has announced two promotions within its financial team. The firm promoted: – Denise Marks to Chief Administrative Partner from Chief Financial Officer, and – Br... |
| 12.04.2017 | SV Life Sciences Rebrands As SV Health Investors, Closes $400M Fund | Boston-based healthcare and life sciences venture capital and growth equity firm SV Life Sciences has changed its name to SV Health Investors and has closed its sixth flagship fund target of $400 million. SV Health Investors’ venture partne... |
| 12.04.2017 | SV Health closes $400M early biotech, med dev and digital health fund | SV Health Investors (formerly SV Life Sciences) has closed its sixth fund, hitting its target of $400 million, as the firm itself also registers a numbers growth. Sponsored by Agilent Technologies How would you like to win free bench space ... |
| 11.04.2017 | SV Health Investors Closes Fund at $400M | SV Health Investors, the venture capital and growth equity firm formerly known as SV Life Sciences, has closed on its sixth flagship fund. The fund closed at its target of $400 million. SV also manages the Dementia Discovery Fund, plus five... |
| 11.04.2017 | SV Health Investors Closes on New Venture Capital Fund, at $400M | In conjunction with the rebranding announcement, SV Health Investors, a Boston, MA-based venture capital and growth equity firm (fka SV Life Sciences), closed on its sixth flagship fund, at $400m. SV VI, like the prior SV funds, will have a... |
| 11.04.2017 | PureTech launches an I/O startup inspired by NYU’s George Miller; SV adopts a new name | → PureTech is launching a new biotech, this time focusing on the immuno-oncology work done by NYU’s George Miller. It’s named Nybo Therapeutics, and like a lot of PureTech upstarts, the announcement is long on reputations/n... |
| 11.04.2017 | SV Health Investors rebranding reflects increased investment in health IT | Looking back at the past five funds, the firm has invested in 30 companies per fund with an average of $15 million invested in those businesses, Hill said. So what are some examples of digital health applications that interest SV Health? “W... |
| 11.04.2017 | SV Health Investors Closes Fund at $400M | SV Health Investors, the venture capital and growth equity firm formerly known as SV Life Sciences, has closed on its sixth flagship fund. The fund closed at its target of $400 million. SV also manages the Dementia Discovery Fund, plus five... |
| 10.04.2017 | SV Life Sciences Rebrands As SV Health Investors | SV Life Sciences, a Boston, MA-based healthcare and life sciences venture capital and growth equity firm, has changed its name to SV Health Investors. The rebrands aims to better reflect the firm’s longstanding strategy and multi-sector foc... |
| 21.10.2016 | Launch of Dementia Discovery Fund New Fund Raises $100 Million to Deliver Novel Approaches to Treatment of Dementia | London, 21 October 2015, The Dementia Discovery Fund (DDF), an innovative new global investment fund to support discovery and development of novel dementia treatments has launched, raising $100 Million from investors including the UK Govern... |
Show more